A study recently published by the International Journal of Chronic Obstructive Pulmonary Disease (COPD), analyzes current recommendations for palliative care (PC) for chronic obstructive pulmonary disease (COPD) patients to determine their level of reliability during an expected 1-year mortality.
PC is typically used for patients with neoplastic diseases and may be used with other therapies to improve symptoms and the overall quality of life. PC has proven to be effective in COPD, but it is more complicated in utilization.
"One of the main barriers for initiating PC in COPD is the unpredictability of vital prognosis in an individual patient," the authors wrote. "Many COPD patients present a gradual deterioration, others stability for years, while a subgroup suffers acute COPD exacerbations."
The study involved 3 main phases to determine the reliability of PC for COPD patients:
Of the 697 patients hospitalized for COPD exacerbation included in the study, 93% were males and had a 1-mortality rate of 17.5%. However, of those whom met the criteria for PC, there was not a statistical significance in mortality differences.
“The main conclusion of our study is that none of the suggested criteria for initiating PC based on an expected poor vital prognosis in COPD patients in the short or medium term offers sufficient reliability, and perhaps, they should be avoided as exclusive criteria for considering PC or at least critically evaluated,” the authors concluded.
Despite the lack of statistical differences, the researchers suggested that the decision to begin PC should be paired with restorative care. Furthermore, PC is often associated with only being necessary for terminal care, but the study recommended considering its applicability when used with other therapies.
Recognizing Symptoms of Myeloproliferative Neoplasms and Clinical Trial Challenges
October 24th 2024There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
Interstitial Lung Abnormalities in Patients With COPD Linked to Cancer, Heart Failure Risks
October 23rd 2024Interstitial lung abnormalities (ILAs) in patients with chronic obstructive pulmonary disease (COPD) are linked to lower lung adenocarcinoma rates but higher rates of other cancers and heart failure.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines
October 22nd 2024Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.
Read More
Neoadjuvant Chemotherapy Becomes Leading Initial Treatment for Advanced Epithelial Ovarian Cancer
October 22nd 2024By 2021, neoadjuvant chemotherapy followed by interval cytoreductive surgery became the most common initial treatment for patients with advanced epithelial ovarian cancer, overtaking primary cytoreductive surgery.
Read More